title: Update of research on drug resistance in small cell lung cancer chemotherapy.
abstract: Small cell lung cancer (SCLC) is characterized by a short cell doubling time, rapid progression and early occurrence of blood-borne and lymph metastasis. The malignancy is the highest of all lung cancer types. Although SCLC has a relatively good initial response to chemotherapy as well as radiotherapy, relapse or disease progression may occur quickly after the initial treatment. Drug resistance, especially multi-drug resistance, is the most important cause of failure of SCLC chemotherapy. This article provides a brief update of research on mechanisms of drug resistance in SCLC and reversal strategies.
authors.affiliation: Department of Medical Oncology, Jinling Hospital, Nanjing, China.
authors.forename: Yi-Tian
authors.initials: YT
authors.lastname: Chen
authors.forename: Bing
authors.initials: B
authors.lastname: Feng
authors.forename: Long-Bang
authors.initials: LB
authors.lastname: Chen
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*